Johnson & Johnson’s Innovative Approach to Enhancing Diversity in Clinical Trials

At DPHARM 2024, Johnson & Johnson (J&J) unveiled their groundbreaking strategies to improve diversity, equity, and inclusion (DE&I) in clinical trials. Afia Afzal, Senior Director of Applied Innovation and Portfolio Management at J&J, shared the company’s comprehensive data-driven approach, which integrates clinical and operational excellence to tackle the historical lack of diversity in clinical trials. This initiative is part of J&J’s broader commitment to advancing health equity and ensuring that clinical research is more representative of diverse populations.

A Data-Driven Strategy for Diversity

Johnson & Johnson’s strategy to enhance diversity in clinical trials is deeply rooted in a data-driven approach to ensure research inclusivity. Afia Afzal highlighted the historical context where many clinical trials have lacked sufficient diversity, limiting the applicability of study results to a broader population. This lack of diversity can lead to skewed data that does not accurately reflect the efficacy and safety of treatments across different demographic groups. To address this, J&J has implemented DE&I modeling within their clinical trials, setting specific diversity targets informed by disease prevalence and healthcare inequities. By doing so, J&J aims to create a more inclusive research environment that accounts for underrepresented groups’ unique health challenges.

The company utilizes advanced modeling and diversity analytics to predict the potential of clinical trial sites and make recommendations based on performance. This predictive capability allows J&J to strategically select sites that are more likely to enroll diverse populations, enhancing the representativeness of their clinical trials. This approach is about identifying the right sites and ensuring that the necessary strategies are in place to support the inclusion of diverse populations throughout the trial process. By focusing on these elements, J&J is working to rectify historical imbalances and ensure that its research findings apply to a broader range of individuals, ultimately contributing to more equitable healthcare outcomes.

Overcoming Bias and Enhancing Inclusivity

Afzal discussed the critical need to address and overcome biases within clinical trials, emphasizing that if historical biases are not addressed, they can inadvertently be carried over into new trials, perpetuating exclusion. To combat this, J&J is actively reviewing its algorithms to ensure they are free from bias, involving a thorough examination of the data used to develop these algorithms to ensure they are representative of the populations they aim to serve. In addition to algorithmic scrutiny, J&J is committed to designing inclusive trials that consider the unique health needs of underrepresented populations. This includes adapting trial protocols to accommodate specific cultural or medical nuances, which can significantly impact the participation and retention of diverse groups in clinical trials.

J&J’s efforts to enhance inclusivity extend to the trial design, ensuring that eligibility criteria are inclusive and reflective of the diverse populations affected by the studied diseases. This holistic approach to trial design is essential for addressing systemic barriers that have historically limited the participation of diverse groups in clinical research. For example, understanding cultural differences in health perceptions and treatment preferences can lead to more effective recruitment strategies and better patient engagement.

Leveraging Analytics for Site Selection

Selecting clinical trial sites is pivotal to J&J’s strategy to enhance diversity. Afzal explained that the company employs a comprehensive analytical approach to site selection, examining historical recruitment data, real-world data, and social determinants of health. This multifaceted analysis helps J&J uncover insights that can improve the enrollment of diverse patients. By identifying sites with high enrollment potential for underrepresented populations, J&J collaborates with these sites to ensure successful patient enrollment. This collaboration is crucial, as it involves working closely with site staff to implement strategies that support the inclusion of diverse populations. For instance, sites may require specialized engagement strategies to reach and recruit patients from diverse backgrounds effectively.

J&J’s approach to site selection is not limited to traditional sites with a history of clinical trial participation. The company is also open to considering research-naive sites with untapped potential for enrolling diverse patients. This openness to exploring new sites is part of J&J’s commitment to expanding the reach of their clinical trials and ensuring they are accessible to a broader range of participants.

Addressing Multiple Factors Affecting Enrollment

Afzal emphasized that diverse enrollment in clinical trials is influenced by many factors, each of which must be carefully considered to achieve meaningful inclusion. She noted that trial design, site location, and patient outreach are all critical components impacting enrollment. For example, a trial’s inclusion and exclusion criteria can either facilitate or hinder the participation of diverse groups, depending on how they are structured. The location of trial sites is another critical factor, as it can affect the accessibility of the trial to potential participants. Sites in areas with high concentrations of diverse populations are more likely to enroll participants from those groups. However, site location alone is insufficient; the site staff’s demographic composition can also play a significant role. Afzal pointed out that patients are more likely to feel comfortable and enroll in trials when they see themselves represented in the healthcare staff.

Patient outreach is another critical area in which J&J is focusing its efforts. The company ensures that trial materials are bilingual and culturally sensitive, which is essential for reaching non-English speaking populations. This approach helps to break down language barriers and improve communication with potential participants. Afzal also highlighted the importance of addressing the social and economic barriers preventing diverse populations from participating in clinical trials. This includes providing support for childcare, transportation, and other logistical challenges that may hinder participation.

Future Directions and Industry Collaboration

Looking to the future, J&J is committed to further enhancing its strategies for diverse recruitment in clinical trials. Afzal outlined the company’s plans to explore real-world data and social determinants of health that are predictive of diverse recruitment. This exploration is part of J&J’s ongoing effort to refine its approach and ensure it is as effective as possible in reaching underrepresented populations. The company is also interested in expanding its efforts beyond the United States despite the challenges of privacy laws and other regulatory hurdles. Afzal acknowledged that accessing non-US real-world data is difficult, but J&J is actively working to overcome these challenges and broaden its global reach.

Collaboration with other industry stakeholders is another crucial aspect of J&J’s plans. Afzal emphasized that enhancing diversity in clinical trials requires a collective effort from the entire industry. By working together, companies can share data, insights, and best practices to drive meaningful change and improve the inclusivity of clinical research. In conclusion, Johnson & Johnson’s innovative approach to enhancing diversity in clinical trials demonstrates a solid commitment to advancing health equity. The company is paving the way for more representative and equitable clinical research through data-driven strategies, a focus on inclusivity, and industry collaboration.